{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:48:44Z","timestamp":1782780524195,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10067-024-07041-z","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T06:02:36Z","timestamp":1719900156000},"page":"2503-2511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study"],"prefix":"10.1007","volume":"43","author":[{"given":"Po-Ku","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Jieh","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung-Liang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-1423","authenticated-orcid":false,"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"7041_CR1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1056\/NEJMp058091","volume":"22","author":"A Arvin","year":"2005","unstructured":"Arvin A (2005) Aging, immunity, and the varicella-zoster virus. N Engl J Med 22:2266\u20132267. https:\/\/doi.org\/10.1056\/NEJMp058091","journal-title":"N Engl J Med"},{"key":"7041_CR2","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ (2014) Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 4:e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833","journal-title":"BMJ Open"},{"key":"7041_CR3","doi-asserted-by":"publisher","first-page":"e006304","DOI":"10.1161\/JAHA.117.006304","volume":"6","author":"TL Liao","year":"2017","unstructured":"Liao TL, Lin CH, Chen HH, Chen YM, Lin CC, Chen DY (2017) Significant associations of neurological complications of herpes zoster with stroke in rheumatoid arthritis patients. J Am Heart Assoc 6:e006304. https:\/\/doi.org\/10.1161\/JAHA.117.006304","journal-title":"J Am Heart Assoc"},{"key":"7041_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG et al (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Therapeutic Adva Vaccines 3:109\u2013120. https:\/\/doi.org\/10.1177\/2051013615599151","journal-title":"Therapeutic Adva Vaccines"},{"key":"7041_CR5","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","volume":"92","author":"K Kawai","year":"2017","unstructured":"Kawai K, Yawn BP (2017) Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc 92:1806\u20131821. https:\/\/doi.org\/10.1016\/j.mayocp.2017.10.009","journal-title":"Mayo Clin Proc"},{"key":"7041_CR6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.23112","volume":"57","author":"AL Smitten","year":"2007","unstructured":"Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA et al (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57:1431\u20131438. https:\/\/doi.org\/10.1002\/art.23112","journal-title":"Arthritis Rheum"},{"key":"7041_CR7","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1086\/598331","volume":"48","author":"JR McDonald","year":"2009","unstructured":"McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE et al (2009) Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 48:1364\u20131371. https:\/\/doi.org\/10.1086\/598331","journal-title":"Clin Infect Dis"},{"key":"7041_CR8","doi-asserted-by":"publisher","first-page":"e0140327","DOI":"10.1136\/bmjopen-2016-014032","volume":"7","author":"TL Liao","year":"2017","unstructured":"Liao TL, Chen YM, Liu HJ, Chen DY (2017) Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open 7:e0140327. https:\/\/doi.org\/10.1136\/bmjopen-2016-014032","journal-title":"BMJ Open"},{"key":"7041_CR9","doi-asserted-by":"publisher","first-page":"vi12","DOI":"10.1093\/rheumatology\/keab609","volume":"60","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y (2021) Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology 60:vi12\u2013vi20. https:\/\/doi.org\/10.1093\/rheumatology\/keab609","journal-title":"Rheumatology"},{"key":"7041_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W (2021) The JAK\/STAT signaling pathway: From bench to clinic. Signal Transduct Target Ther 6:402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1","journal-title":"Signal Transduct Target Ther"},{"key":"7041_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR et al (2019) Safety and efficacy of tofacitinib up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Thera 21:89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2","journal-title":"Arthritis Res Thera"},{"key":"7041_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74:333\u2013340. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206478","journal-title":"Ann Rheum Dis"},{"key":"7041_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","volume":"23","author":"H Kameda","year":"2021","unstructured":"Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M et al (2021) Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther 23:9. https:\/\/doi.org\/10.1186\/s13075-020-02387-6","journal-title":"Arthritis Res Ther"},{"key":"7041_CR14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5years: integrated analysis of data from the global clinical trials. Ann Rheum 76:1253\u20131262. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210457","journal-title":"Ann Rheum"},{"key":"7041_CR15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/ard-2023-223916","volume":"82","author":"R Fleischmann","year":"2023","unstructured":"Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C et al (2023) Safety profile of Upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis 82:1130\u20131141. https:\/\/doi.org\/10.1136\/ard-2023-223916","journal-title":"Ann Rheum Dis"},{"key":"7041_CR16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H et al (2017) Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 69:1960\u20131968. https:\/\/doi.org\/10.1002\/art.40189","journal-title":"Arthritis Rheumatol"},{"key":"7041_CR17","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL (2016) Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75:1843\u20131847. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209131","journal-title":"Ann Rheum Dis"},{"key":"7041_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP et al (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 58:1755\u20131766. https:\/\/doi.org\/10.1093\/rheumatology\/kez087","journal-title":"Rheumatology (Oxford)"},{"key":"7041_CR19","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1093\/rheumatology\/kead079","volume":"62","author":"T Uchida","year":"2023","unstructured":"Uchida T, Iwamoto N, Fukui S, Morimoto S, Aramaki T, Shomura F et al (2023) Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study. Rheumatology 62:3358\u20133365. https:\/\/doi.org\/10.1093\/rheumatology\/kead079","journal-title":"Rheumatology"},{"key":"7041_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/14397595.2017.1307899","volume":"28","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Ishii T, Cai Z, Schlichting D, Rooney T, Macias W (2018) Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single blind, extension study. Mod Rheumatol 28:20\u201329. https:\/\/doi.org\/10.1080\/14397595.2017.1307899","journal-title":"Mod Rheumatol"},{"key":"7041_CR21","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","volume":"60","author":"AF Dagnew","year":"2021","unstructured":"Dagnew AF, Rausch D, Herv\u00e9 C, Zahaf T, Levin MJ, Schuind A, ZOE-50\/70 study group (2021) Efficacy and Serious Adverse Events Profile of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-Existing Potential Immune-Mediated Diseases: A Pooled Post Hoc Analysis on Two Parallel Randomized Trials. Rheumatology 60:1226\u20131233. https:\/\/doi.org\/10.1093\/rheumatology\/keaa424","journal-title":"Rheumatology"},{"key":"7041_CR22","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.13846","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.13846","journal-title":"Ann Rheum Dis"},{"key":"7041_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348. https:\/\/doi.org\/10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"key":"7041_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/aje\/kwx245","volume":"187","author":"R Baxter","year":"2018","unstructured":"Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E et al (2018) Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. Am J Epidemiol 187:161\u2013169. https:\/\/doi.org\/10.1093\/aje\/kwx245","journal-title":"Am J Epidemiol"},{"key":"7041_CR25","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00018-017-2520-2","volume":"74","author":"N Raftery","year":"2017","unstructured":"Raftery N, Stevenson NJ (2017) Advances in anti-viral immune defense: revealing the importance of the IFN JAK\/STAT pathway. Cell Mol Life Sci 74:2525\u20132625. https:\/\/doi.org\/10.1007\/s00018-017-2520-2","journal-title":"Cell Mol Life Sci"},{"key":"7041_CR26","doi-asserted-by":"publisher","unstructured":"Mok CC, So H, Yim CW, To CH, Lao WN, Wong SPY et al (2023) Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong biologics registry. Rheumatology (Oxford) 63:358\u2013365. https:\/\/doi.org\/10.1093\/rheumatology\/kead198","DOI":"10.1093\/rheumatology\/kead198"},{"key":"7041_CR27","doi-asserted-by":"publisher","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","volume":"14","author":"Q Xu","year":"2023","unstructured":"Xu Q, He L, Yin Y (2023) Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systemic review and network meta-analysis. Front Pharmacol 14:1241954. https:\/\/doi.org\/10.3389\/fphar.2023.1241954","journal-title":"Front Pharmacol"},{"key":"7041_CR28","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1097\/RHU.0000000000001749","volume":"28","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Marques FB (2022) The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol 28:e407\u2013e414. https:\/\/doi.org\/10.1097\/RHU.0000000000001749","journal-title":"J Clin Rheumatol"},{"key":"7041_CR29","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/acr.23769","volume":"71","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H et al (2019) Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. Arthritis Care Res 71:1249\u20131254. https:\/\/doi.org\/10.1002\/acr.23769","journal-title":"Arthritis Care Res"},{"key":"7041_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00296-022-05270-6","volume":"43","author":"CG Gialouri","year":"2023","unstructured":"Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D (2023) Herpes zoster in patients with infammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int 43:421\u2013435. https:\/\/doi.org\/10.1007\/s00296-022-05270-6","journal-title":"Rheumatol Int"},{"key":"7041_CR31","doi-asserted-by":"publisher","first-page":"e22504","DOI":"10.1097\/MD.0000000000022504","volume":"99","author":"YJ Chen","year":"2020","unstructured":"Chen YJ, Chen YM, Huang WN, Chen HH, Liao TL, Chen JP et al (2020) Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan. Medicine 99:e22504. https:\/\/doi.org\/10.1097\/MD.0000000000022504","journal-title":"Medicine"},{"key":"7041_CR32","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s10067-022-06096-0","volume":"41","author":"W Choi","year":"2022","unstructured":"Choi W, Ahn SM, Kim YG, Lee CK, Yoo B, Hong S (2022) Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors. Clin Rheumatol 41:1659\u20131663. https:\/\/doi.org\/10.1007\/s10067-022-06096-0","journal-title":"Clin Rheumatol"},{"key":"7041_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L et al (2020) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80:304\u2013311. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510","journal-title":"Ann Rheum Dis"},{"key":"7041_CR34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","volume":"44","author":"PG Conaghan","year":"2021","unstructured":"Conaghan PG, Mysler E, Tanaka Y, Da Silva-Tillmann B, Shaw T, Liu J, Ferguson R et al (2021) Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. Drug Saf 44:515\u2013530. https:\/\/doi.org\/10.1007\/s40264-020-01036-w","journal-title":"Drug Saf"},{"key":"7041_CR35","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/S0002-9440(10)63575-4","volume":"163","author":"D Theil","year":"2003","unstructured":"Theil D, Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O et al (2003) Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 163:2179\u20132184. https:\/\/doi.org\/10.1016\/S0002-9440(10)63575-4","journal-title":"Am J Pathol"},{"key":"7041_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.4236\/ijcm.2018.99060","volume":"9","author":"OP Olabode","year":"2018","unstructured":"Olabode OP, Sebastine O, Akinboro AO (2018) Herpes zoster in diverse situations: a review. Int J Clin Med 9:716\u2013736. https:\/\/doi.org\/10.4236\/ijcm.2018.99060","journal-title":"Int J Clin Med"},{"key":"7041_CR37","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00296-022-05146-9","volume":"42","author":"S Zubchenko","year":"2022","unstructured":"Zubchenko S, Kril I, Nadizhko O, Matsyura O, Chopyak V (2022) Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int 42:1523\u20131530. https:\/\/doi.org\/10.1007\/s00296-022-05146-9","journal-title":"Rheumatol Int"},{"key":"7041_CR38","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s11845-021-02714-z","volume":"191","author":"J Katz","year":"2022","unstructured":"Katz J, Yue S, Xue W (2022) Herpes simplex and herpes zoster viruses in COVID-19 patients. Irish J Med Sci 191:1093\u20131097. https:\/\/doi.org\/10.1007\/s11845-021-02714-z","journal-title":"Irish J Med Sci"},{"key":"7041_CR39","doi-asserted-by":"publisher","first-page":"868","DOI":"10.55563\/clinexprheumatol\/pudtpo","volume":"39","author":"GM Guidelli","year":"2021","unstructured":"Guidelli GM, Viapiana O, Luciano N, De Santis M, Bofni N, Quartuccio L et al (2021) Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study. Clin Exp Rheumatol 39:868\u2013873. https:\/\/doi.org\/10.55563\/clinexprheumatol\/pudtpo","journal-title":"Clin Exp Rheumatol"},{"key":"7041_CR40","doi-asserted-by":"publisher","unstructured":"Takahashi N, Asai S, Kobayakawa T, Kaneko A, Watanabe T, Kato T et al (2020) Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. Sci Rep 10:21907. https:\/\/doi.org\/10.1038\/s41598-020-78925-8","DOI":"10.1038\/s41598-020-78925-8"},{"key":"7041_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3947\/ic.2020.52.2.252","volume":"52","author":"YB Seo","year":"2020","unstructured":"Seo YB, Moon SJ, Jeon CH, Song JY, Sung YK, Jeong SJ et al (2020) The Practice Guideline for vaccinating Korean patients with autoimmune inflammatory rheumatic disease. Infect Chemother 52:252\u2013280. https:\/\/doi.org\/10.3947\/ic.2020.52.2.252","journal-title":"Infect Chemother"},{"key":"7041_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79:39\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882","journal-title":"Ann Rheum Dis"},{"key":"7041_CR43","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","volume":"60","author":"AF Dagnew","year":"2021","unstructured":"Dagnew AF, Rausch D, Herv\u00e9 C, Zahaf T, Levin MJ, Schuind A et al (2021) Efficacy and Serious Adverse Events Profile of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-Existing Potential Immune-Mediated Diseases: A Pooled Post Hoc Analysis on Two Parallel Randomized Trials. Rheumatology 60:1226\u20131233. https:\/\/doi.org\/10.1093\/rheumatology\/keaa424","journal-title":"Rheumatology"},{"key":"7041_CR44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC et al (2023) 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 75:449\u2013464. https:\/\/doi.org\/10.1002\/acr.25045","journal-title":"Arthritis Care Res"},{"key":"7041_CR45","doi-asserted-by":"publisher","first-page":"6967","DOI":"10.3390\/ijms24086967","volume":"24","author":"V Venerito","year":"2023","unstructured":"Venerito V, Stefanizzi P, Cantarini L, Lavista M, Galeone MG, Di Lorenzo A et al (2023) Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study. Int J Mol Sci 24:6967. https:\/\/doi.org\/10.3390\/ijms24086967","journal-title":"Int J Mol Sci"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07041-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07041-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07041-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:22:53Z","timestamp":1726755773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07041-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7041"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07041-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}